ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2015
The prognostic value of regadenoson myocardial perfusion imaging.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia.American heart journal · 2022Trial
- Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2016Trial
- Quality metrics for single-photon emission computed tomography myocardial perfusion imaging: an ASNC information statement.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Review
- Comparison of left ventricle mechanical dyssynchrony parameters in ischemic and non-ischemic patients usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Prognostic value of absent left ventricular ejection fraction reserve with regadenoson SPECT MPI.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Evolution of symptoms in patients with stable angina after normal regadenoson myocardial perfusion imaging: The Radionuclide Imaging and Symptomatic Evolution study (RISE).Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The diagnostic and prognostic value of near-normal perfusion or borderline ischemia on stress myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Retrospective studies and definition of endpoints.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The evolution of the prognostic value of regadenoson SPECT myocardial perfusion imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Stress testing and myocardial perfusion imaging for patients after recovery from severe COVID-19 infection requiring hospitalization: A single-center experience.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Cases from a busy nuclear cardiology laboratory.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Myocardial infarction assessment by surface electrocardiography.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The prognostic value of myocardial perfusion imaging in patients with type 2 myocardial infarction.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Prevalence of abnormal SPECT myocardial perfusion imaging during the COVID-19 pandemic.European journal of nuclear medicine and molecular imaging · 2021Article
- Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- What is this image? 2021: Image 5 result : Progression of myocardial ischemia to scar on serialJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Severe myocardial ischemia in a patient with diabetes mellitus and left bundle branch block.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundRegadenoson (REGA), a selective adenosine A2A receptor agonist, is the most widely used stress agent for SPECT myocardial perfusion imaging (MPI) in the United States. The diagnostic accuracy of REGA MPI is comparable to Adenosine MPI, but its prognostic value is not well defined.
methodsWe categorized 1,400 patients (700 consecutive normal and 700 consecutive abnormal REGA-MPIs) into 4 groups based on the perfusion defect size using automated quantitative analysis: Group 1: normal perfusion; Group 2: <10% of left ventricle; Group 3: 10%-20%; Group 4: >20%. The primary outcome was a composite of cardiac death, myocardial infarction (MI), and late coronary revascularization (CR >90 days after MPI).
resultsOf the 1,400 patients (42% male, 37% diabetes, 21% heart failure, 26% end-stage renal disease), the primary outcome occurred in 23% (17% cardiac death, 4% MI, 6% late CR) during 46 ± 18 months of follow-up and 8% had early CR (within 90 days of MPI). Early CR occurred in 0.4%, 9%, 17%, and 17% and the primary outcome in 10%, 27%, 31%, and 43% in Groups 1-4, respectively (P < .001 for both). In an adjusted Cox proportional model, the hazard ratio for the primary outcome was 2.68 (1.77-4.06), 3.32 (2.28-4.83), and 4.05 (2.78-5.91) for Groups 2-4 compared to Group 1.
conclusionREGA MPI provides powerful prognostic information that has important implications in patient management and can guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.